D. Boral Capital Reaffirms "Buy" Rating for Anixa Biosciences (NASDAQ:ANIX)

Key Points

• D. Boral Capital has maintained a "Buy" rating on Anixa Biosciences, setting a target price of $10.00, which suggests a potential upside of 178.55% from the current stock price.
• Anixa Biosciences recently reported earnings of ($0.07) per share, exceeding analyst estimates of ($0.10), indicating a positive outlook for the company.
• Insider trading activity shows that Director Lewis H. Titterton, Jr. purchased 10,000 shares at an average price of $3.08, demonstrating confidence in the company's future performance.

Anixa Biosciences (NASDAQ:ANIX - Get Free Report)'s stock had its "buy" rating restated by investment analysts at D. Boral Capital in a research report issued on Tuesday,Benzinga reports. They currently have a $10.00 target price on the stock. D. Boral Capital's target price points to a potential upside of 178.55% from the stock's previous close.

ANIX has been the topic of several other reports. HC Wainwright reiterated a "buy" rating and issued a $7.00 price objective on shares of Anixa Biosciences in a research note on Thursday, September 11th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Anixa Biosciences in a research note on Saturday, September 27th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $9.00.

Anixa Biosciences Stock Performance

Shares of ANIX stock traded up $0.34 during mid-day trading on Tuesday, reaching $3.59. The company's stock had a trading volume of 272,094 shares, compared to its average volume of 107,639. The firm's 50-day moving average is $3.13 and its two-hundred day moving average is $3.02. The company has a market cap of $118.17 million, a P/E ratio of -10.47 and a beta of 0.69. Anixa Biosciences has a 1-year low of $2.07 and a 1-year high of $4.20.

Anixa Biosciences (NASDAQ:ANIX - Get Free Report) last posted its earnings results on Wednesday, September 10th. The company reported ($0.07) earnings per share for the quarter, beating analysts' consensus estimates of ($0.10) by $0.03. Sell-side analysts anticipate that Anixa Biosciences will post -0.41 EPS for the current year.

Insiders Place Their Bets

In other Anixa Biosciences news, Director Lewis H. Titterton, Jr. bought 10,000 shares of the firm's stock in a transaction dated Thursday, July 31st. The shares were bought at an average price of $3.08 per share, for a total transaction of $30,800.00. Following the completion of the acquisition, the director owned 953,334 shares of the company's stock, valued at approximately $2,936,268.72. This trade represents a 1.06% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders acquired 35,000 shares of company stock valued at $110,700 in the last quarter. Corporate insiders own 25.30% of the company's stock.

Institutional Trading of Anixa Biosciences

Large investors have recently made changes to their positions in the business. NewEdge Advisors LLC bought a new stake in shares of Anixa Biosciences during the second quarter worth $33,000. Millennium Management LLC bought a new stake in shares of Anixa Biosciences during the fourth quarter worth $26,000. Benjamin Edwards Inc. bought a new stake in shares of Anixa Biosciences during the second quarter worth $37,000. Marshall Wace LLP bought a new stake in shares of Anixa Biosciences during the second quarter worth $39,000. Finally, Private Advisor Group LLC bought a new stake in shares of Anixa Biosciences during the first quarter worth $35,000. Institutional investors own 29.13% of the company's stock.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.